Trial Profile
A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs BMS 986360 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 06 Jun 2023 Status changed from completed to discontinued.
- 04 Feb 2022 Status changed from active, no longer recruiting to completed.
- 06 Oct 2021 Planned End Date changed from 14 Feb 2024 to 31 Dec 2021.